MAGE-TAB Version 1.1 Comment[MetaboBank accession] MTBKS223 Study Title Gut microbiome-based prediction of autoimmune neuroinflammation Study Description We found that the relative abundances of commensal taxa across distinct communities are poorly suited to assess the disease-mediating property of a given microbiota. Instead, the presence of certain microbial risk factors allowed us to determine the probability of severe disease, but failed to predict the individual disease course. We investigated multiple other microbiota-associated characteristics by applying 16S rRNA gene sequencing, metatranscriptomic and metabolomic approaches, as well as in-depth analysis of host immune responses and intestinal barrier integrity-associated readouts. In summary, our data suggest that common taxonomic analysis approaches should be refined by taxonomic network analyses or combined with microbiota function-related readouts to reliably assess disease predisposition of a given host-microbiota combination. Experimental Design disease state design Experimental Factor Name treatment disease Experimental Factor Type treatment disease Person Last Name Shinji Mitsuko Person First Name Fukuda Komatsu Person Mid Initials Person Affiliation Institute for Advanced Biosciences, Keio University Institute for Advanced Biosciences, Keio University Person Roles submitter submitter PubMed ID Publication DOI https://doi.org/10.1101/2023.04.14.536901 Protocol Name Sample collection Extraction Capillary Electrophoresis 1 Capillary Electrophoresis 2 Mass spectrometry 1 Mass spectrometry 2 Data processing Metabolite identification Protocol Type Sample collection Extraction Capillary Electrophoresis Capillary Electrophoresis Mass spectrometry Mass spectrometry Data processing Metabolite identification Protocol Description "For gnotobiotic experiments, female germ-free (GF) C57BL/6N mice were purchased from Taconic Biosciences, Germany at the age of 4 to 8 weeks. All animals were housed and bred in the GF facility of the University of Luxembourg, supervised by the ethical committee of the University of Luxembourg (AEEC). Mice were randomly allocated to the different experimental groups and were housed in ISO-cages in groups with a maximum of five animals per cage. Water and diets were provided ad libitum. Before start of experiments, GF status of all mice was confirmed via anaerobic and aerobic microbial culturing of fecal samples in NHB and BHI liquid medium. All 14 bacterial strains of the synthetic microbiota (SM) were cultured and processed under anaerobic conditions using a Type B vinyl anaerobic chamber from LabGene, Switzerland, as published in detail previously (20). A total of six different SM combinations were used to colonize GF mice. Non-colonized GF mice were used as a control group. Intragastric gavage and verification of proper colonization of administered strains was performed as described in detail elsewhere (20). Details on the 14 different used strains are summarized in Supplementary Table 1. Mice were maintained on a standard mouse chow (fiber-rich; "FR") diet included a crude fiber content of 3,9% (SAFE, Augy, France, version A04, product code U8233G10R). All diets were sterilized by 25 kGy gamma irradiation. At the age of 4 to 8 weeks, mice were colonized with various SM combination. Mice were then either induced with experimental autoimmune encephalomyelitis (labelled as "+ EAE" in the manuscript) 20 days after the initial gavage or were euthanized for organ harvest 25 days after the initial gavage without induction of experimental autoimmune encephalomyelitis (labelled as "- EAE" in the manuscript). Mice were immunized using the Hooke Kit MOG35-55/CFA Emulsion PTX (Hooke Laboratories, Ref.: EK-2110) according to manufacturer's instructions. In brief, mice were immunized with a subcutaneous injection of a myelin oligodendrocyte glycoprotein-derived peptide (MOG35-55) and complete Freund's adjuvant (CFA) delivered in pre-filled syringes. Subcutaneous injection of two times 100 µL (200 µL in total) of MOG/CFA (1 mg mL-1 MOG35-55 and 2-5 mg mL-1 killed mycobacterium tuberculosis H37Ra/mL (CFU)) mixture was performed on two sides bilateral in each of the mouse's flank. Additionally, Pertussis toxin (PTX) solution was injected on the day of MOG peptide immunization and 48 hours after the first injection. Glycerol-buffer stabilized PTX was diluted in sterile PBS for application of 400 ng PTX (Gnotobiotic experiments) or 150 ng (Experiments under SPF conditions) by intraperitoneal injection of 100 µL PTX solution. The EAE clinical symptom scores were assessed daily according to the scheme depicted in Extended Figure S7. Mice of all groups ("- EAE" and "+ EAE") were subjected to terminal anesthesia through intraperitoneal application of a combination of midazolam (5 mg kg-1), ketamine (100 mg kg-1), and xylazine (10 mg kg-1) followed by cardiac perfusion with ice-cold PBS. Cecal content were harvested for downstream analysis." Cecal metabolites were extracted from about 10 mg of a freeze-dried sample by vigorous shaking with 500 µL of 100% MeOH supplemented with 20 µM methionine sulfone as well as 20 µM D-camphor-10-sulfonic acid, as per internal standards. Four 3 mm zirconia beads (BioSpec Products, Bartlesville, OK, USA) and about 100 mg of 0.1 mm zirconia/silica beads (BioSpec Products, Bartlesville, OK, USA) were added to this mix. Afterwards, samples were shaked vigorously for 5 minutes using a Shake Master NEO (BioSpec Products, Bartlesville, Oklahoma, U.S.A.). Next, 500 µL of chloroform and 200 µL of Milli-Q water were added, and samples were shaked vigorously for 5 minutes again and followed by centrifugation (4600 × g for 30 min at 4°C). Afterwards, we transferred the obtained supernatant to a filter column with a 5 kDa cut-off (Ultrafree MC-PLHCC 250/pk) for downstream metabolite analysis (Human Metabolome Technologies, Tsuruoka, Yamagata, Japan). The resulting flow-through was vacuum dried. 50 µL of Milli-Q water containing reference compounds (200 µM 3-aminopyrrolidine and 200 µM trimesic acid) was used to dissolve the residue. "Extracted metabolites were separated by an Agilent 1600 capillary electrophoresis system (Agilent Technologies, Waldbronn, Germany) in positive mode. A fused silica capillary (Molex Incorporated, Illinois, USA) was used as the separation capillary. A 1 M formic acid solution was used as electrolyte solution for CE separation.Approximately 5 nl of sample solution were injected at 50 mbar for 5 s, and 30 kV of voltage was applied. The capillary temperature was maintained at 20 °C, and the sample tray was cooled below 5 °C." "Extracted metabolites were separated by an Agilent 7100 capillary electrophoresis system (Agilent Technologies, Waldbronn, Germany) in negative mode. A COSMO(+) capillary (Nacalai Tesque, Kyoto, Japan) was used as the separation capillary. A 50 mM ammonium acetate solution (pH 8.5) was used as electrolyte solution for CE separation. Sample solution (30 nl) was injected at 50 mbar for 30 s and -30 kV of voltage was applied." "The levels of extracted metabolites were measured by CE-TOF/MS in positive mode using an Agilent G1969 TOF LC/MS system (Agilent Technologies, Santa Clara, CA, USA). Methanol-water (50% v/v) containing 0.1 µM Hexakis(2,2-difluoroethoxy)phosphazene was delivered as the sheath liquid at 10 μl/min. ESI-TOFMS was operated in the positive ion mode, and the capillary voltage was set at 4,000 V. A flow rate of heated dry nitrogen gas (heater temperature 300°C) was maintained at 7 psig. In TOFMS, the fragmentor, skimmer, and Oct RFV voltage were set at 75 V, 50 V, and 125 V, respectively. Automatic recalibration of each acquired spectrum was performed using reference masses of reference standards. The methanol adduct ion (m/z 66.063061) and Hexakis(2,2-difluoroethoxy)phosphazene (m/z 622.028963) provided the lock mass for exact mass measurements. Exact mass data were acquired at a rate of 10 spectra/s over a 50-1,000 m/z range." "The levels of extracted metabolites were measured by CE-TOF/MS in negatine mode using an Agilent 6224 TOF LC/MS system (Agilent Technologies, Santa Clara, CA, USA). Ammonium acetate (5 mM) in 50% methanol-water (v/v) containing 0.01 μM Hexakis(2,2-difluoroethoxy) phosphazene was delivered as the sheath liquid at 10 μl/min. ESI-TOFMS was conducted in the negative ion mode; the capillary voltage was set at 3,500 V. For TOFMS, the fragmentor, skimmer, and Oct RFV voltage were set at 100 V, 50 V, and 500 V, respectively. Automatic recalibration of each acquired spectrum was performed using reference masses of standards. 2CH3COOH13C isotope (m/z 120.038339) and Hexakis(2,2-difluoroethoxy)phosphazene+CH3COOH (m/z 680.035541) provided the lock mass for exact mass measurements. Exact mass data were acquired at a rate of 10 spectra/s over a 50-1,000 m/z range." "Raw data were analyzed with our proprietary software called MasterHands, which has already been used in several CE-TOF-MS-based profiling studies. The data analysis workflow starting with the raw data included noise-filtering, baseline correction, peak detection and integration of the peak area from sliced electropherograms (the width of each electropherogram was 0.02 m/z). Such functions are commonly used by data processing software such as MassHunter from Agilent Technologies, or XCMS for liquid chromatography-MS or gas chromatography-MS data. The accurate m/z value for each peak detected within the time domain was calculated with Gaussian curve-fitting to the mass spectrum on the m/z domain peak. The alignment of peaks in multiple measurements was done by dynamic programming (DP)-based techniques with slight modifications. The method picked up a few representative peaks using the Douglas-Peucker algorithm from unit m/z electropherograms, found corresponding peaks across multiple samples by DP, and optimized the numerical parameters of the normalization function for CE-migration. Instead of representative peaks, we used the detected peaks with accurate m/z values and regarded the peaks whose m/z difference was less than 20 ppm as ones that were derived from the same electropherograms. All peak areas were divided by the area of the internal standard (relative area) to normalize the signal intensities, and to avoid injection-volume bias and mass-spectrometry detector sensitivity bias among multiple measurements. Undetected peaks with a threshold signal-to-noise ratio of 2 were given a peak area of 0. The peaks derived from salt and neutral molecules were found in the first and the last few minutes, respectively. Then, isotopic compounds, ringing, spikes and fragment and adduct ions were eliminated and the peak data sets were compared across the sample profiles and aligned according to m/z and migration time." The peaks were identified with our proprietary software called MasterHands, based on the matched m/z values and normalized migration times of the corresponding standard compounds if available. Of the peaks that did not match with any standard compounds, the concomitant peaks, such as isotopic peaks and fragment peaks, were removed based on the difference in m/z values and the normalized migration time of the two peaks with an error tolerance of 20 ppm and 0.01 min to yield only the peaks, or referred to as components, which might be derived from metabolites. Although CE-TOF-MS provides accurate molecular mass at the milli m/z level, the m/z alone is seldom successful to identify the metabolite. Therefore, we used their m/z values and the migration times predicted by the Artificial Neural Networks (ANNs) to identify the metabolite. Briefly, the ANN model was first trained using the measured migration times of standard compounds and molecular descriptors with the net charge calculated from the pKa values. The trained ANN model then predicted the migration times of the candidate metabolites. Here, we used compounds available from the Kyoto Encyclopedia of Gene and Genomics (KEGG) databaseand the Human Metabolome Database (HMDB) as candidates. The composition formulae obtained using the measured mass spectrometry and the matched candidates were confirmed by their isotope distribution patterns. Protocol Parameters Post extraction;Derivatization CE instrument;Autosampler model;Column model;Column type CE instrument;Autosampler model;Column model;Column type Scan polarity;Scan m/z range;Instrument;Ion source;Mass analyzer Scan polarity;Scan m/z range;Instrument;Ion source;Mass analyzer Protocol Hardware Protocol Software Public Release Date 2023-07-13 Term Source Name Term Source File Term Source Version SDRF File MTBKS223.sdrf.txt Comment[Study type] metabolite profiling Comment[Experiment type] capillary electrophoresis-mass spectrometry Comment[Submission type] CE-MS Comment[BioProject] PRJDB16184 Comment[Related study] Comment[Contributor] Comment[Submission Date] 2023-06-30 Comment[Last Update Date] 2023-07-13